ReviewCurrent osteoporosis reports2026
Interferon-JAK-STAT Axis in Bone Metabolism.
Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewEmerging evidence indicates that interferons (IFNs) are crucial links between immune activation and skeletal remodeling, highlighting their roles in immune–skeletal interactions. This review highlights the IFN–JAK-STAT (the Janus kinase–signal transducer and activator of transcription) axis as a central signaling hub mediating osteoimmunology and provides an updated overview of its molecular mechanisms and its therapeutic relevance. RECENT
findingsInterferons play a crucial role in health and disease and consist of three major classes: Type I, II, and III IFNs. All IFNs transduce their signaling through the JAK–STAT pathway. Dysregulated JAK–STAT signaling is a key clinical feature of various pathological conditions, including autoimmune diseases and cancers. Several IFN-targeted and IFN-based therapies have been approved by the FDA for these indications. However, the assessment of skeletal events associated with IFN-related therapeutic strategies remains incomplete, which represents a gap in our knowledge. The role of IFNs in bone metabolism depends on the context and stage, and IFNs can yield opposing effects on skeletal health. A better understanding of the complex regulatory mechanisms downstream of IFN signaling under physiological and pathological conditions is critical for developing targeted interventions to restore the balance between immune response and skeletal health.
Indexed as
Identifiers
41886008What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.